Trial Search Results

Phase 1 Trial of Oral Ixabepilone

This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer

Stanford is currently not accepting patients for this trial.

Lead Sponsor:



  • Drug: Ixabepilone (oral formulation)


Phase 1


Inclusion Criteria:

   - Males and females, 18 or older

   - Histologically or cytologically confirmed diagnosis of solid tumor malignancy

   - Measurable or non-measurable disease as defined by Response Evaluation Criteria In
   Solid Tumors (RECIST) criteria

   - Karnofsky Performance Status (KPS) of 70-100

   - Recovered from toxicities resulting from previous therapies

Exclusion Criteria:

   - More than 3 prior cytotoxic regimens in the metastatic setting

   - Current or recent gastrointestinal (GI) disease that would impact the absorption of
   study drug

   - Inability to swallow whole capsules

   - Inadequate hepatic and renal function

   - Function exposure to any epothilone

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study